ALK and non-small cell lung carcinoma: While the program has enhanced the adoption of molecular testing for NSCLC in Ontario, the routine integration of comprehensive genomic profiling, both at diagnosis and upon progression in patients with ALK-positive NSCLC, is still evolving and varies across different healthcare settings [78,79].